Sudden Sensorineural Hearing Loss (SSNHL)

Sudden sensorineural hearing loss (SSNHL) is a rapid loss of hearing that arises in the inner ear or the hearing nerve rather than the middle ear. Clinical trials have defined it as a loss of at least 30 dB over three contiguous frequencies developing in three days or less, and the 2012 American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) guideline describes diagnosing presumptive idiopathic SSNHL when audiometry confirms a 30-dB loss at three consecutive frequencies and no underlying condition is found. The 2019 guideline update reports that SSNHL affects 5 to 27 per 100,000 people a year, with about 66,000 new cases a year in the United States, and that over 90% of cases are idiopathic (PubMed PMID: 31369359). A US insurance-claims study found incidence rising with age, from 11 per 100,000 in people younger than 18 to 77 per 100,000 at 65 and older (PubMed PMID: 24232060). The guideline describes sudden hearing loss as a symptom that often prompts an urgent or emergent visit and emphasizes the urgency of evaluation and of starting treatment, if treatment is offered.

Table of Contents

  1. What Is SSNHL?
  2. Causes and Risk Factors
  3. Symptoms and Clinical Presentation
  4. Diagnosis and Evaluation
  5. Prognosis and Recovery
  6. Treatment: Corticosteroids
  7. Intratympanic Steroid Therapy
  8. Adjunctive and Emerging Therapies
  9. Excluding Acoustic Neuroma
  10. Rehabilitation and Long-Term Management
  11. Key Research Papers
  12. Featured Videos

What Is SSNHL?

Idiopathic SSNHL is a clinical diagnosis: a sudden deafness of cochlear or retrocochlear origin with no clear precipitating cause (PubMed PMID: 23818120). The definition used in the 1980 double-blind steroid trial was not less than a 30-dB loss over three contiguous frequencies in three days or less (PubMed PMID: 7002129); the 2002 valacyclovir trial used the same 30 dB, three-frequency, under-three-days threshold (PubMed PMID: 11981385).

The first strong recommendation of the 2019 AAO-HNS guideline update is that clinicians distinguish sensorineural from conductive hearing loss when a patient first presents with sudden hearing loss. The update asks for audiometry as soon as possible, within 14 days of symptom onset, to confirm the diagnosis (PubMed PMID: 31369359). Whether hours or days matter is debated: a prospective Paris study of 326 idiopathic cases seen within 7 days found no significant difference in outcome whether treatment started within the first 24 hours or within the first week, and its authors concluded the condition cannot be considered an otologic emergency (PubMed PMID: 16151335).

The guideline update recommends that the history and examination look specifically for bilateral sudden hearing loss, recurrent episodes, and focal neurologic findings, which point away from the idiopathic form (PubMed PMID: 31369359).

Causes and Risk Factors

The 2019 guideline update reports that over 90% of SSNHL is idiopathic (PubMed PMID: 31369359). Several mechanisms have been proposed; none is established for most patients.

Viral Infection

A study of 18 adult human temporal bones found latent herpes simplex virus type 1 (HSV-1) DNA in every bone, including 9 of 18 spiral ganglion samples; the authors read this as support for a viral cause of sudden hearing loss (PubMed PMID: 9756341). The authors of the 1980 steroid trial also proposed viral cochlitis as the primary cause (PubMed PMID: 7002129). Treatment trials have not borne this out: a Cochrane review of four randomized trials (257 participants) found no statistically significant advantage from antiviral drugs (PubMed PMID: 22895957).

Vascular Occlusion

A 2024 review describes the labyrinthine artery as the only end artery supplying the inner ear, with three branches, and calls vascular pathologies (cochlear ischemia or infarction) one of the most likely causes of idiopathic SSNHL. It reports that many studies link SSNHL with atherosclerosis and cardiovascular risk factors such as diabetes, hypertension and dyslipidemia, and that later stroke risk may be elevated compared with controls. It also notes that bleeding inside the labyrinth can mimic idiopathic SSNHL and needs careful MRI interpretation (PubMed PMID: 38850720).

Autoimmune Inner Ear Disease

Autoimmune and other inflammatory inner ear diseases, such as Cogan syndrome, are treated mainly with corticosteroids (PubMed PMID: 10399889). In a review of 47 patients with autoimmune inner ear disease, 69.7% responded to oral prednisone, and the anti-heat shock protein 70 (HSP70) antibody test had a sensitivity of 54.5% and specificity of 42.9%, so the authors judged its clinical usefulness limited (PubMed PMID: 23817208). A meta-analysis found only three eligible diagnostic studies of this antibody, with potential bias, and concluded that an accurate laboratory test is still needed (PubMed PMID: 23295728).

Perilymphatic Fistula

A perilymphatic fistula is a leak of inner-ear fluid through the cochlear windows. In a German series of 90 patients with SSNHL who underwent exploratory middle-ear surgery, 10 (11%) had a fistula, close to the 13.6% in the authors' literature review; sealing the membranes was not followed by a significant improvement in hearing (PubMed PMID: 32614760).

Retrocochlear Tumors

Idiopathic SSNHL is usually diagnosed after retrocochlear causes such as vestibular schwannoma (acoustic neuroma) have been excluded (PubMed PMID: 38850720). In a 10-year Chinese series of 1,249 patients with SSNHL who had MRI, 14 (1.12%) had a vestibular schwannoma (PubMed PMID: 32234257). In Korean national insurance data, 25.8% of 5,751 people with vestibular schwannoma had an earlier record of SSNHL, significantly more than matched controls (PubMed PMID: 38088318).

Ototoxic Medications

Drug-related hearing damage (ototoxicity) is a separate, identifiable cause. A 1985 review covers the ototoxicity of aminoglycoside antibiotics, loop diuretics, acetylsalicylic acid (aspirin), quinine, erythromycin and cisplatin (PubMed PMID: 3872601).

Symptoms and Clinical Presentation

The core symptom is a sudden loss of hearing. The 2019 guideline update notes that it is frequently, but not always, accompanied by tinnitus and/or vertigo (PubMed PMID: 31369359).

Associated Symptoms

Findings the Guideline Flags

The 2019 guideline update singles out bilateral sudden hearing loss, recurrent episodes and focal neurologic findings as features to look for in the history and examination (PubMed PMID: 31369359). The 2024 vascular review notes that people with idiopathic SSNHL may have a higher later risk of stroke than controls (PubMed PMID: 38850720).

Diagnosis and Evaluation

The 2019 AAO-HNS guideline update sets out the diagnostic steps. Among its strong recommendations are to distinguish sensorineural from conductive loss at presentation, and against routine head CT in the initial evaluation and against routine laboratory tests (PubMed PMID: 31369359).

Audiometry

The guideline update recommends audiometry as soon as possible, within 14 days of onset, to confirm the diagnosis, and follow-up audiometry at the end of treatment and within 6 months of completing it (PubMed PMID: 31369359). The initial audiogram also carries prognostic information: in a prospective study, low-frequency losses did better than high-frequency losses, and hearing at 8 kHz and speech discrimination scores helped predict outcome (PubMed PMID: 889223).

Imaging for Retrocochlear Causes

The guideline update recommends evaluating for retrocochlear pathology with magnetic resonance imaging (MRI) or auditory brainstem response (ABR) testing. It names MRI, CT if MRI cannot be done, and secondarily ABR as the modalities, excludes audiometric follow-up alone as a reasonable workup, and does not specify a time frame for the testing (PubMed PMID: 31369359). In the Chinese series, the audiogram pattern, hearing level and hearing recovery did not reliably predict which patients had a vestibular schwannoma, and the authors judged MRI more suitable than ABR in their setting (PubMed PMID: 32234257).

Laboratory Testing

The guideline update makes a strong recommendation against routine laboratory tests, citing new studies that confirm the lack of benefit of nontargeted laboratory testing (PubMed PMID: 31369359). Research protocols have used specific tests: the 2002 valacyclovir trial's pretreatment evaluation included a complete blood count, blood chemistry and a fluorescent treponemal antibody (syphilis) test (PubMed PMID: 11981385). An elevated erythrocyte sedimentation rate was a prognostic indicator in two older natural-history studies (PubMed PMID: 6325838; PubMed PMID: 889223).

Vestibular Function Testing

In the 1977 natural-history study, vestibular test abnormalities correlated very poorly with hearing outcome, with the exception of reduced caloric responses (PubMed PMID: 889223).

Prognosis and Recovery

Many people recover without treatment. In a prospective study, 65% recovered completely to functional hearing levels spontaneously, regardless of treatment, most within 14 days (PubMed PMID: 889223). A 2008 trial report gives the untreated recovery rate as 32 to 65% (PubMed PMID: 18401285). In an 8-year prospective study of 225 patients, 45% had normal or complete recovery and 28% had late ear complications (PubMed PMID: 6325838). Prognostic factors reported in these studies:

Better Prognosis

Worse Prognosis

Because of this high spontaneous recovery rate, the 1984 study concluded there was still no evidence that treatment achieved a result better than spontaneous recovery (PubMed PMID: 6325838). The 2019 guideline update makes a strong recommendation that clinicians explain the natural history, the benefits and risks of treatment and the limits of the evidence, and that people with residual hearing loss or tinnitus be counseled about audiologic rehabilitation (PubMed PMID: 31369359).

Treatment: Corticosteroids

The 2019 AAO-HNS guideline update lists corticosteroids as initial therapy within 2 weeks of symptom onset as an option, a lower grade than its recommendations and strong recommendations (PubMed PMID: 31369359); the 2012 guideline also graded them an option (PubMed PMID: 22383545). The evidence is mixed. A 2013 Cochrane review found only three placebo-controlled trials (267 participants), all at high risk of bias: one showed improvement in 61% of steroid-treated patients versus 32% of controls, while the other two showed no effect, and the reviewers concluded the value of steroids remains unclear (PubMed PMID: 23818120). The 1980 double-blind trial found a statistically significant effect in patients with moderate hearing losses (PubMed PMID: 7002129).

Regimens Used in Trials

Trials have used different regimens. The 2011 multicenter trial gave oral prednisone 60 mg/day for 14 days with a 5-day taper (PubMed PMID: 21610239). The 2002 valacyclovir trial gave prednisone 80 mg/day for 4 days, tapered over 8 days (PubMed PMID: 11981385). The Paris cohort received intravenous corticosteroids at 1 mg/kg per day for 6 days (PubMed PMID: 16151335).

Timing

The guideline update frames the corticosteroid option as starting within 2 weeks of symptom onset (PubMed PMID: 31369359). The Paris cohort found no significant outcome difference between treatment started within 24 hours and treatment started within the first week (PubMed PMID: 16151335).

Side Effects and Risk Profiles

A 2022 Cochrane review notes that adverse effects were poorly reported in the trials, and that intratympanic treatment (eardrum perforation, pain, dizziness or vertigo) and systemic treatment (for example, blood glucose problems) carry different risk profiles (PubMed PMID: 35867413). In one salvage series, the 5 patients with diabetes had a recovery rate after intratympanic dexamethasone (20%) not significantly different from patients without diabetes (28.6%) (PubMed PMID: 17202923).

Intratympanic Steroid Therapy

Intratympanic therapy delivers a corticosteroid by injection through the eardrum into the middle ear. In a guinea-pig study, hydrocortisone, methylprednisolone and dexamethasone all reached much higher concentrations in the cochlear fluids after topical (middle-ear) application than after oral or intravenous dosing, with methylprednisolone showing the best profile; the authors suggested this route might avoid the side effects of high blood levels (PubMed PMID: 10399889). That is an animal result.

Primary IT Therapy

In the 2011 multicenter trial by Rauch and colleagues (250 patients at 16 practices, hearing loss of 50 dB or more within 14 days of onset), intratympanic methylprednisolone (40 mg/mL, four injections over 14 days) was not inferior to oral prednisone. Hearing improved by 28.7 dB with injections and 30.7 dB with oral prednisone at 2 months; non-inferiority was defined as a difference under 10 dB (PubMed PMID: 21610239). A 2022 Cochrane review of 16 studies (1,108 participants) found little to no difference between intratympanic and systemic corticosteroids as first treatment in the proportion whose hearing improved (moderate-certainty evidence). Injections may increase vertigo or dizziness and probably increase ear pain, and persistent eardrum perforation occurred in 0% to 3.9% (PubMed PMID: 35867413). Adding injections to systemic steroids may have a small effect on hearing thresholds (low-certainty evidence) (PubMed PMID: 35867413); a 51-patient randomized trial reported better odds of recovery with the combination than with high-dose prednisone alone (PubMed PMID: 18401285).

Salvage IT Therapy

For incomplete recovery 2 to 6 weeks after onset, the 2019 guideline update recommends that clinicians offer intratympanic steroids; this is graded a recommendation, not a strong recommendation (PubMed PMID: 31369359). As second-line therapy, the 2022 Cochrane review found low-certainty evidence that injections, compared with no treatment or placebo, may give a much higher proportion of improved hearing (risk ratio 5.55) but only a small change in hearing threshold (about 9 dB); persistent perforation ranged from 0% to 4.2% and vertigo or dizziness at injection from 6.7% to 33% (PubMed PMID: 35867413). In a 40-patient salvage series using one dexamethasone injection, 27.5% improved by the study's criteria, no one injected after 36 days recovered, and earlier injection was linked with better results (PubMed PMID: 17202923).

Protocols Used in Studies

Protocols vary between studies: four injections of methylprednisolone 40 mg/mL over 14 days in the 2011 trial (PubMed PMID: 21610239), and a single injection of dexamethasone 24 mg/mL in the salvage series (PubMed PMID: 17202923). Ear pain at the time of injection was reported in 10.5% to 27.1% of participants in two first-line trials (PubMed PMID: 35867413).

Adjunctive and Emerging Therapies

Antiviral Agents

In the multicenter randomized trial by Tucci and colleagues (2002), adding valacyclovir (1 g three times a day for 10 days) to prednisone gave no more benefit than prednisone with placebo; 84 of 105 enrolled patients were evaluable (PubMed PMID: 11981385). A Cochrane review of four randomized trials (257 participants) found no statistically significant advantage from antivirals (PubMed PMID: 22895957). The 2019 AAO-HNS guideline update makes a strong recommendation against routinely prescribing antivirals (PubMed PMID: 31369359).

Hyperbaric Oxygen Therapy

Hyperbaric oxygen (HBO) therapy is studied on the idea that it may improve oxygen supply to the inner ear. A 2012 Cochrane review (Bennett and colleagues) included seven small trials (392 participants) of generally poor quality. For recent-onset idiopathic SSNHL, HBO did not significantly raise the chance of a 50% improvement in hearing threshold, but did raise the chance of a 25% improvement (risk ratio 1.39; number needed to treat 5) and gave an average threshold 15.6 dB better. The reviewers called the clinical significance unclear, urged cautious interpretation, and found no evidence of benefit when hearing loss or tinnitus had lasted about six months (PubMed PMID: 23076907). The 2019 guideline update lists HBO combined with steroids as an option, within 2 weeks of onset as initial therapy or within 1 month as salvage therapy (PubMed PMID: 31369359).

Vasodilators and Rheological Agents

A systematic review of five studies (611 patients) concluded that vasodilators have no beneficial effect in idiopathic SSNHL, although some evidence suggested better hearing when they were combined with steroids (PubMed PMID: 29283102). The 2019 guideline update makes a strong recommendation against routinely prescribing thrombolytics, vasodilators or vasoactive substances (PubMed PMID: 31369359). The 2024 vascular review lists prostaglandin E1, defibrinogenation therapy and hydrogen inhalation among treatments in use and states that there is currently no evidence-based treatment for idiopathic SSNHL (PubMed PMID: 38850720).

Hearing Devices

For lasting hearing loss, devices are rehabilitation rather than treatment of the underlying condition. Cochlear implantation for single-sided deafness is covered under Rehabilitation below.

Excluding Acoustic Neuroma

Idiopathic SSNHL is usually diagnosed only after retrocochlear causes such as vestibular schwannoma (acoustic neuroma) have been excluded (PubMed PMID: 38850720). Key findings:

Rehabilitation and Long-Term Management

For hearing loss or tinnitus that remains after treatment, the 2019 AAO-HNS guideline update makes a strong recommendation that clinicians counsel patients about the possible benefits of audiologic rehabilitation and other supportive measures (PubMed PMID: 31369359).

Mild-to-Moderate Residual Loss

The 2012 guideline's strong recommendation for incomplete recovery covered counseling about amplification and hearing-assistive technology (PubMed PMID: 22383545).

Profound Unilateral Loss (Single-Sided Deafness)

A 2023 meta-analysis of 36 studies (796 adults with single-sided deafness) found that cochlear implants improved speech recognition in noise and sound localization (root-mean-square error about 25 degrees smaller), reduced tinnitus severity on the Tinnitus Handicap Inventory, and improved self-rated spatial hearing and quality of life (PubMed PMID: 36791341).

Tinnitus Management

A 2026 review protocol describes effective tinnitus treatment after idiopathic SSNHL as limited, with sound therapies such as masking and retraining therapy under study (PubMed PMID: 42114875). In adults with single-sided deafness, cochlear implant use was linked with lower tinnitus severity (PubMed PMID: 36791341).

Vestibular Rehabilitation

Vestibular rehabilitation is an exercise-based approach to dizziness and imbalance. A Cochrane review of 39 studies (2,441 participants) with unilateral peripheral vestibular dysfunction, not limited to SSNHL, found moderate to strong evidence that it is safe and effective; it reduced the frequency of dizziness compared with control or no intervention (odds ratio 2.67) (PubMed PMID: 25581507).

Key Research Papers

  1. Stachler RJ, Chandrasekhar SS, Archer SM, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg. 2012;146(3 Suppl):S1–S35. — PubMed PMID: 22383545
  2. Chandrasekhar SS, Tsai Do BS, Schwartz SR, et al. Clinical Practice Guideline: Sudden Hearing Loss (Update). Otolaryngol Head Neck Surg. 2019;161(1_suppl):S1–S45. — PubMed PMID: 31369359
  3. Rauch SD, Halpin CF, Antonelli PJ, et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA. 2011;305(20):2071–2079. — PubMed PMID: 21610239
  4. Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study. Arch Otolaryngol. 1980;106(12):772–776. — PubMed PMID: 7002129
  5. Battaglia A, Burchette R, Cueva R. Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otol Neurotol. 2008;29(4):453–460. — PubMed PMID: 18401285
  6. Bennett MH, Kertesz T, Perleth M, Yeung P, Lehm JP. Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus. Cochrane Database Syst Rev. 2012;10:CD004739. — PubMed PMID: 23076907
  7. Nakashima T, Itoh A, Misawa H, Ohno Y. Clinicoepidemiologic features of sudden deafness diagnosed and treated at university hospitals in Japan. Otolaryngol Head Neck Surg. 2000;123(5):593–597. — PubMed PMID: 11077347
  8. Haynes DS, O'Malley M, Cohen S, et al. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope. 2007;117(1):3–15. — PubMed PMID: 17202923
  9. Kuhn M, Heman-Ackah SE, Shaikh JA, Roehm PC. Sudden sensorineural hearing loss: a review of diagnosis, treatment, and prognosis. Trends Amplif. 2011;15(3):91–105. — PubMed PMID: 21606048
  10. Byl FM Jr. Sudden hearing loss: eight years' experience and suggested prognostic table. Laryngoscope. 1984;94(5 Pt 1):647–661. — PubMed PMID: 6325838
  11. Chau JK, Cho JJ, Fritz DK. Evidence-based practice: management of adult sensorineural hearing loss. Otolaryngol Clin North Am. 2012;45(5):941–958. — PubMed PMID: 22980677
  12. Mattox DE, Simmons FB. Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol. 1977;86(4 Pt 1):463–480. — PubMed PMID: 889223
  13. Plontke SK, Meisner C, Agrawal S, et al. Intratympanic corticosteroids for sudden sensorineural hearing loss. Cochrane Database Syst Rev. 2022;7(7):CD008080. — PubMed PMID: 35867413
  14. Wei BP, Stathopoulos D, O'Leary S. Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev. 2013;(7):CD003998. — PubMed PMID: 23818120
  15. Tucci DL, Farmer JC Jr, Kitch RD, Witsell DL. Treatment of sudden sensorineural hearing loss with systemic steroids and valacyclovir. Otol Neurotol. 2002;23(3):301–308. — PubMed PMID: 11981385
  16. Awad Z, Huins C, Pothier DD. Antivirals for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev. 2012;(8):CD006987. — PubMed PMID: 22895957
  17. Alexander TH, Harris JP. Incidence of sudden sensorineural hearing loss. Otol Neurotol. 2013;34(9):1586–1589. — PubMed PMID: 24232060
  18. Huy PT, Sauvaget E. Idiopathic sudden sensorineural hearing loss is not an otologic emergency. Otol Neurotol. 2005;26(5):896–902. — PubMed PMID: 16151335
  19. Yu H, Li H. Association of vertigo with hearing outcomes in patients with sudden sensorineural hearing loss: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2018;144(8):677–683. — PubMed PMID: 29931169
  20. Yang W, Mei X, Li X, et al. The prevalence and clinical characteristics of vestibular schwannoma among patients treated as sudden sensorineural hearing loss: a 10-year retrospective study in southern China. Am J Otolaryngol. 2020;41(4):102452. — PubMed PMID: 32234257
  21. Jeong J, Lee YH, Kim S, et al. Sudden sensorineural hearing loss and facial palsy in patients with vestibular schwannoma based on the population data of Korea. J Int Adv Otol. 2023;19(6):468–471. — PubMed PMID: 38088318
  22. Tsuzuki N, Wasano K. Idiopathic sudden sensorineural hearing loss: a review focused on the contribution of vascular pathologies. Auris Nasus Larynx. 2024;51(4):747–754. — PubMed PMID: 38850720
  23. Schulz P, Arbusow V, Strupp M, et al. Highly variable distribution of HSV-1-specific DNA in human geniculate, vestibular and spiral ganglia. Neurosci Lett. 1998;252(2):139–142. — PubMed PMID: 9756341
  24. Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope. 1999;109(7 Pt 2):1–17. — PubMed PMID: 10399889
  25. Matsuoka AJ, Harris JP. Autoimmune inner ear disease: a retrospective review of forty-seven patients. Audiol Neurootol. 2013;18(4):228–239. — PubMed PMID: 23817208
  26. Ianuale C, Cadoni G, De Feo E, et al. A systematic review and meta-analysis of the diagnostic accuracy of anti-heat shock protein 70 antibodies for the detection of autoimmune hearing loss. Otol Neurotol. 2013;34(2):214–219. — PubMed PMID: 23295728
  27. Heilen S, Lang CP, Warnecke A, et al. Exploratory tympanotomy in sudden sensorineural hearing loss for the identification of a perilymphatic fistula - retrospective analysis and review of the literature. J Laryngol Otol. 2020;134(6):501–508. — PubMed PMID: 32614760
  28. Koegel L Jr. Ototoxicity: a contemporary review of aminoglycosides, loop diuretics, acetylsalicylic acid, quinine, erythromycin, and cisplatinum. Am J Otol. 1985;6(2):190–199. — PubMed PMID: 3872601
  29. Bravenboer de Sousa M, Cazemier S, Stegeman I, Thomeer H. Use of vasodilators in idiopathic sudden sensorineural hearing loss: a systematic review. J Int Adv Otol. 2017;13(3):399–403. — PubMed PMID: 29283102
  30. Daher GS, Kocharyan A, Dillon MT, Carlson ML. Cochlear implantation outcomes in adults with single-sided deafness: a systematic review and meta-analysis. Otol Neurotol. 2023;44(4):297–309. — PubMed PMID: 36791341
  31. McDonnell MN, Hillier SL. Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. Cochrane Database Syst Rev. 2015;1(1):CD005397. — PubMed PMID: 25581507
  32. Ren Q, Luo H, Li J, et al. Efficacy of sound therapy on tinnitus in idiopathic sudden sensorineural hearing loss: a systematic review and meta-analysis protocol. BMJ Open. 2026;16(5):e117521. — PubMed PMID: 42114875

PubMed Topic Searches

The following PubMed topic searches retrieve current peer-reviewed literature on Sudden Sensorineural Hearing Loss.

  1. PubMed: SSNHL corticosteroid treatment
  2. PubMed: Intratympanic steroid injection SSNHL
  3. PubMed: SSNHL prognosis and spontaneous recovery
  4. PubMed: Sudden hearing loss acoustic neuroma MRI workup
  5. PubMed: SSNHL viral and vascular etiology
  6. PubMed: SSNHL hyperbaric oxygen therapy
  7. PubMed: Single-sided deafness cochlear implant and bone-anchored devices
  8. PubMed: Idiopathic SSNHL randomized controlled trials

Back to Table of Contents

Connections

Back to Table of Contents